New tool supports discovery of differentially methylated regions and epigenetic target identification for cancer metastasis and human development research Human methylome panel facilitates development ...

NTRK fusion positive colorectal cancer as a unique subset of CRC with high tumor mutation burden and microsatellite instability. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I.

GUANGZHOU, China, Oct. 11, 2021 /PRNewswire/ -- The Twist Alliance Pan-Cancer Methylation Panel (Pan-Cancer Panel), a solution for pan-cancer study including DNA methylation library preparation and ...

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of the ...

Predicting overall survival (OS) in patients (pts) with penile squamous cell carcinoma (PSCC) undergoing regional lymph node dissection (LND) ± multimodal therapy. This is an ASCO Meeting Abstract ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...

Globally, the epigenomics market is estimated to reach $4.1 billion by 2012, up from $263.2 million in 2006, according to a March 2007 report by BCC Research. The key market segments include research ...

A minimally invasive esophageal sampling device has excellent potential for the early diagnosis of Barrett's esophagus (BE) and the earlier detection of esophageal cancer in high-risk patients, new ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...